eTheRNA inks mRNA partnership with Merck KGaA

The collaboration will study the application of eTheRNA’s mRNA and LNP-delivery platforms to disease areas picked by Germany’s Merck.

The research collaboration will target messenger RNA (mRNA) therapeutics using eTheRNA’s mRNA and lipid nano particle (LNP) technologies in various model systems. If successful, mRNA encoding antigens will be nominated by Merck KGaA relevant for human diseases.

“Etherna开发了一个临床证明,临床证明是调节在所有免疫反应的心脏的树突细胞-T细胞相互作用的平台,”Etherna告诉我们。

图像:图库照片秘密

“这是通过将MRNA化学解决方案与我们独特的Trimix技术相结合来实现的。此外,Etherna具有创新性,分化的脂质制剂,使有针对性的递送和量身定制的生物分布,与竞争LNP的临床前示范。最后,我们有专利保护的过程技术和GMP认证的制造能力,承诺更快地开发温度稳定的mRNA产品。“

该伙伴关系将在位于比利时的Etherna的研发网站以及Merck Kgaa拥有的未公开设施。根据Etherna的说法,该公司“都有能够进行计划的研究计划的强大和资助的研究团队,因此不需要扩大员工或设备来服务这笔交易。

eTheRNA expects to move to disease-specific investigations next year once evaluations are complete.

COVID-19 push

而当然mRNA vaccines have reaped success and earned validation through COVID-19 jab victory, the future of mRNA vaccines goes beyond COVID-19 itself. With an abundance of funding and companies bolstering their mRNA capabilities across the globe, it isn’t surprising that companies are partnering to discover mRNA therapeutics.

“基于mRNA的治疗方法是解决新兴条件的有价值的额外选择,例如Covid-19,以及无需足够治疗的当前人类疾病的长期列表。“发言人说,这项研究合作将探讨在扩大疾病范围内使用靶向mRNA治疗剂的可能性。”

Leave a Reply